GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it will present highlights from the ...

Ghent, Belgium – October 8, 2025 – Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has secured a EUR 1 million ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly reached a deal with Confo Therapeutics to gain licensing to Confo’s non-opioid neuropathic pain candidate, CFTX-1554, the companies announced Thursday. In the deal, Confo will receive $630 ...

Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium – June 15, 2026 – Confo Therapeutics, a clinical-stage ...

Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate Tiered royalties payable ...

Almost two years after finally pulling the plug on a big non-opioid painkiller programme, Eli Lilly has dipped another toe into the water with a small licensing deal with Belgian start-up, Confo ...

Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH ...

Discovery of highly potent and selective antibody-based GPCR agonists targeting Melanocortin 4 Receptor (MC4R), a key regulator for hunger and satiety, using Confo's proprietary technology platform ...

Ghent, Belgium - April 30, 2026 - Confo Therapeutics, a leader in the development of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first patients were dosed in a ...